Opexa Therapeutics (OPXA), a biopharmaceutical company, develops personalized cellular therapies to treat multiple sclerosis (MS) based on its proprietary T-cell technology. Its leading therapy candidate includes Tcelna, a novel T-cell immunotherapy, which is in Phase IIb clinical development for the treatment of patients with secondary progressive MS. OPXA was formerly known as PharmaFrontiers Corp. and changed its name to Opexa Therapeutics in June 2006 < founded in 2003> and is based in The Woodlands, Texas.
May 14, 2013
Opexa Therapeutics (OPXA) Q1/13 Results – SELL and then wait until it settles to re-enter!
May 10, 2013
Opexa (OPXA), will report financial results
February 7, 2013
Opexa Therapeutics (OPXA) Prices $3.25 M Unit Offering
February 5, 2013
Merck Serono granted option for exclusive license from Opexa (OPXA) - UP +249%
September 12, 2012
Opexa (OPXA), Secondary Progressive Multiple Sclerosis (SPMS) trial initiates
August 16, 2012
Earnings Report Card, Q2/12, Regenerative Medicine Universe
August 13, 2012
Opexa Therapeutics (OPXA) Q2/12 Results
May 21, 2012
Opexa (OPXA) …What’s up... a Rebranding?
May 16, 2012
Earnings Report Card, Q1/12, Regenerative Medicine Universe
May 15, 2012
Opexa (OPXA) Q1/12 Results and Highlights
35 companies, 1 interpreter!
Insight, foresight and recommendation
Opexa (OPXA) – OPXA’s P2b clinical trial of Tcelna® (imilecleucel-T) in secondary progressive multiple sclerosis (SPMS) (Abili-T trial) is nearing completion. Top line data is expected in early Q4/16. The final dose was administered to the last patient in 2/16 and approximately 98% of all patient visits have now been completed. The Abili-T clinical trial is being conducted at 35 clinical sites in the U.S. and Canada. Opexa has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for Tcelna in SPMS. For Q1/16 OPXA reported a net loss of -$2.1 M, or -$0.31 per share, compared to a net loss of -$3.4 M or -$0.95 per share for Q1/15. RECOMMENDATION: BUY
buy
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2025 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.